Online citations, reference lists, and bibliographies.
← Back to Search

Challenges And Controversies In The Diagnosis Of Mesothelioma: Part 1. Cytology-only Diagnosis, Biopsies, Immunohistochemistry, Discrimination Between Mesothelioma And Reactive Mesothelial Hyperplasia, And Biomarkers

D. Henderson, G. Reid, S. Kao, N. van Zandwijk, S. Klebe
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The detection of neoplastic invasion remains the linchpin for a clear diagnosis of malignant mesothelioma. Cytology-only diagnosis of epithelioid mesothelioma on aspirated effusion fluid remains controversial. A major problem is poor sensitivity, although cytodiagnosis is achievable in many cases at a high order of specificity, especially when a large volume of effusion fluid is submitted for cytological evaluation, enabling the preparation of cell-block sections for immunohistochemical investigation and when the cytological findings can be correlated with imaging studies to assess the anatomical distribution of the lesion and evidence of nodularity of the pleural disorder and, in some cases, to demonstrate evidence of invasion. Although ‘positive’ and ‘negative’ immunohistochemical markers have proved remarkably effective in distinguishing between epithelioid mesothelioma and secondary carcinoma and other malignant tumours metastatic to serosal membranes, no mesothelial marker has 100% sensitivity and specificity for mesothelioma diagnosis, so that panels of ‘positive’ antibodies and markers with negative predictive value are required. At present, no tissue or serum marker (including the molecular detection of p16/CDKN2A) has been proved to have sufficient specificity, consistency and reproducibility that it can replace evidence of invasion as the decisive marker for diagnosis when there is any uncertainty concerning a diagnosis of epithelioid mesothelioma and in the case of atypical fibrous lesions of the pleura (especially collagen-rich lesions, namely fibrous pleuritis vs desmoplastic mesothelioma), in which even the assessment of invasion can be problematical as illustrated in part 2 of this review.
This paper references
10.1007/978-3-642-10862-4_10
Early stages of mesothelioma, screening and biomarkers.
S. Klebe (2011)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1007/978-0-387-72114-9_14
Cytopathology of Pulmonary Neoplasia
N. P. Ohori (2008)
10.1111/j.1365-2559.2011.04036.x
Mesothelial markers in high‐grade breast carcinoma
E. Duhig (2011)
10.1038/modpathol.3800478
Immunocytochemical detection of XIAP in body cavity effusions and washes
M. Wu (2005)
10.1097/PAT.0b013e3283445e67
Molecular biomarkers in malignant mesothelioma: state of the art
S. Kao (2011)
10.1515/CCLM.2010.066
Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels
A. Rai (2010)
10.1097/JTO.0b013e318180477b
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
10.1038/modpathol.3800736
D2-40 and calretinin—a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation
Marc Hinterberger (2007)
10.1097/01.pas.0000165529.78945.dc
Localized Malignant Mesothelioma
T. Allen (2005)
10.1002/cncr.23034
Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma
L. Greillier (2007)
10.1080/00313020802579250
Diagnosis of epithelial mesothelioma using tree‐based regression analysis and a minimal panel of antibodies
S. Klebe (2009)
10.1097/00000478-200111000-00008
The Role of Desmin and N-Cadherin in Effusion Cytology: A Comparative Study Using Established Markers of Mesothelial and Epithelial Cells
B. Davidson (2001)
10.1177/172460081002500307
Comparison between Plasma and Serum Osteopontin Levels: Usefulness in Diagnosis of Epithelial Malignant Pleural Mesothelioma
A. Cristaudo (2010)
10.1136/thoraxjnl-2012-203043
Pleurodesis outcome in malignant pleural mesothelioma
E. Fysh (2013)
10.1007/s00428-007-0375-x
Cytological diagnosis of malignant mesothelioma—improvement by additional analysis of hyaluronic acid in pleural effusions
L. Welker (2007)
10.1158/1078-0432.CCR-10-1929
Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden
J. Creaney (2010)
A diagnosis of malignant pleural mesothelioma can be made by effusion fluid cytology: results of a 20 year audit. Pathology 2013;45:44–8
A Segal (2013)
The pathology of mesothelioma, including immunohistology and ultrastructure
DW Henderson (1992)
10.1378/chest.11-2657
Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion.
E. Fysh (2012)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1515/CCLM.2010.306
Biomarkers for early detection of mesothelioma in asbestos-exposed subjects
E. Park (2010)
10.1002/dc.21489
Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry
Xue-ying Su (2011)
10.1046/j.1365-2559.2000.00981.x
Anti‐mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms
R. Attanoos (2000)
10.1002/1097-0142(20011115)92:10<2727::AID-CNCR1627>3.0.CO;2-B
The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas
T. Tot (2001)
10.1038/sj.bjc.6604879
Occupational, domestic and environmental mesothelioma risks in the British population: a case–control study
C. Rake (2009)
10.1038/modpathol.2008.45
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
S. Chiosea (2008)
10.1007/978-0-387-72114-9_12
Neoplasms of the Pleura
S. Hammar (2008)
Impact of renal failure on the tumor markers of mesothelioma, N-ERC/mesothelin and osteopontin.
K. Shiomi (2011)
10.1097/JTO.0b013e31820db377
Serial Measurements of Mesothelioma Serum Biomarkers in Asbestos-Exposed Individuals: A Prospective Longitudinal Cohort Study
K. Hollevoet (2011)
10.1164/rccm.200802-258OC
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
E. Park (2008)
10.1136/jcp.2010.076794
FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma
C. Chung (2010)
10.1136/thorax.57.2.187-a
Statement on malignant mesothelioma in the UK
M. Robinson (2002)
10.1007/978-3-642-10862-4_4
Biopsy techniques for the diagnosis of mesothelioma.
J. Walters (2011)
10.1309/LX7NFRDXY1JQF9R1
Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.
M. Wu (2007)
10.1056/NEJMc1213514
Fibulin-3 as a biomarker for pleural mesothelioma.
H. Pass (2013)
10.1038/modpathol.2009.180
Sarcomatoid mesothelioma: a clinical–pathologic correlation of 326 cases
S. Klebe (2010)
10.1309/AJCPP5R2ZJZKCLWN
The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
S. Monaco (2011)
10.1158/1055-9965.EPI-08-0422
Serum Levels of Soluble Mesothelin-Related Peptides in Malignant and Nonmalignant Asbestos-Related Pleural Disease: Relation with Past Asbestos Exposure
J. R. Portal (2009)
10.1056/NEJMc1213514
Fibulin-3 as a biomarker for pleural mesothelioma.
K. Hollevoet (2013)
10.1378/chest.11-0129
The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.
Kevin Hollevoet (2012)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.1056/NEJME058176
Serum osteopontin levels--is it time to screen asbestos-exposed workers for pleural mesothelioma?
M. Cullen (2005)
10.1164/rccm.200907-1020OC
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
K. Hollevoet (2010)
10.1016/J.ATHORACSUR.2004.05.007
Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
R. Bueno (2004)
10.1007/BF03256303
Biomarkers for Malignant Pleural Mesothelioma
L. Greillier (2012)
Dail and Hammar's pathology pathology
N P Ohori (2008)
10.1001/jama.2012.5535
Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial.
H. E. Davies (2012)
10.1097/JTO.0b013e31820ce2c7
Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma
S. Kao (2011)
10.1038/modpathol.3800732
Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma
Y. Kato (2007)
10.2165/1250444-200812060-00004
Biomarkers for malignant pleural mesothelioma: current status.
L. Greillier (2008)
10.1002/(SICI)1096-9896(199910)189:2<251::AID-PATH412>3.0.CO;2-F
The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis
P. Cury (1999)
International mesothelioma panel
E Brambilla (2006)
10.1002/DC.20208
The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: A comparative study
R. Saad (2005)
10.1016/J.LUNGCAN.2005.03.020
Soluble mesothelin-related protein--a blood test for mesothelioma.
B. Robinson (2005)
10.1111/j.1365-2559.2011.04031.x
Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma
G. Powell (2011)
Occupational, domestic and environmental mesothelioma risks in Britain
J. Peto (2009)
10.1097/PAT.0b013e32835bc848
A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit
A. Segal (2013)
10.1093/AJCP/110.3.397
Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review.
D. Henderson (1998)
10.1002/dc.21303
The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma
E. Rakha (2010)
10.1097/JTO.0b013e3182272294
Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma
K. Hollevoet (2011)
10.1309/AJCPWFW7O1FVFLKT
Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
J. Shen (2009)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1002/dc.21398
Diagnostic usefulness of EMA, IMP3, and GLUT‐1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations
K. Ikeda (2011)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1510/icvts.2010.255893
What is the best way to diagnose and stage malignant pleural mesothelioma?
I. Zahid (2011)
10.1097/PAS.0b013e318218985b
Oncofetal Protein IMP3, a New Diagnostic Biomarker to Distinguish Malignant Mesothelioma From Reactive Mesothelial Proliferation
M. Shi (2011)
10.1111/j.1365-2559.2008.03099.x
The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma
R. Attanoos (2008)
10.1097/JTO.0b013e3182114aa0
Indwelling pleural catheter: changing the paradigm of malignant effusion management.
Y. Lee (2011)
10.5858/arpa.2012-0112-ra
The Separation of Benign and Malignant Mesothelial Proliferations
A. Churg (2012)
Mesothelioma. In: Travis
A Churg (2004)
10.5694/mja11.10125
Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation
Nola J. Olsen (2011)
Pathology and genetics of tumours of the lung , pleura, thymus and heart
W. D. Travis (2004)
10.1016/S0140-6736(03)13079-6
Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial
N. Maskell (2003)
10.1046/j.1365-2559.1997.5460776.x
Pathology of malignant mesothelioma
R. Attanoos (1997)
10.1111/j.1365-2559.1992.tb00430.x
Intermediate filament expression in mesotheliomas: leiomyoid mesotheliomas are not uncommon
F. Mayall (1992)
10.1043/1543-2165-133.8.1317
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
10.1378/CHEST.111.1.106
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
A. Renshaw (1997)
10.1002/dc.21146
Evidence‐based guidelines to optimize the selection of antibody panels in cytopathology: Pleural effusions with malignant epithelioid cells
Danielle E Westfall (2010)
10.1136/oem.2007.034280
Mortality of former crocidolite (blue asbestos) miners and millers at Wittenoom
A. Musk (2007)
10.1378/chest.09-0884
Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial.
M. Metintas (2010)
10.1038/modpathol.2008.125
Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review
S. Klebe (2008)
10.1016/J.HOC.2005.09.007
Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein.
J. Creaney (2005)
10.1136/thx.2007.087619
BTS statement on malignant mesothelioma in the UK, 2007
(2007)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1378/CHEST.07-0013
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
J. Creaney (2007)
Australian Institute of Health and Welfare. Cancer incidence projections Australia
(2011)
Cancer incidence projections, Australia 2002 to 2011
I. Mcdermid (2005)
Fine needle aspiration cytology of malignant mesothelioma.
G. Sterrett (1987)
10.1016/j.lungcan.2009.02.023
A local anaesthetic video-assisted thoracoscopy service: prospective performance analysis in a UK tertiary respiratory centre.
A. Medford (2009)
The value of immunohistochemical markers in differentiating benign from malignant mesothelial lesions
A Acurio (2008)
10.1053/j.semtcvs.2009.06.007
Current status of screening for malignant pleural mesothelioma.
H. Pass (2009)
10.1046/j.1365-2559.2003.01686.x
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2
R. Attanoos (2003)
10.5858/arpa.2012-0214-OA
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
A. Husain (2013)
10.1111/j.1365-2559.2006.02442.x
Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports
J. King (2006)
10.1097/MCP.0b013e3283474121
The diminishing role of surgery in pleural disease
H. E. Davies (2011)
10.1080/01913120601172489
Malignant Mesothelioma with Intracytoplasmic Crystalline Inclusions
J. Goedhals (2007)
10.1007/BF00195777
Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium
K. Segers (1994)
10.1158/1078-0432.CCR-06-0472
Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma
M. Onda (2006)
10.1043/1543-2165(2008)132[23:CMVBHU]2.0.CO;2
Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Virganeyce Lyons-Boudreaux (2008)
10.1016/j.humpath.2009.04.030
IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
K. Ikeda (2010)
10.1136/thx.2006.068114
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
J. Creaney (2007)
10.1158/1078-0432.CCR-07-0629
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
10.1016/j.lungcan.2008.02.012
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
K. Iwahori (2008)
10.1007/978-0-387-68792-6
Dail and Hammar’s Pulmonary Pathology
J. Tomashefski (2008)
10.1016/0046-8177(95)90254-6
Expression of muscle actins in diffuse mesotheliomas.
I. T. Kung (1995)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
Unusual histological types and anatomic sites of mesothelioma
DW Henderson (1992)
10.1111/j.1440-1827.2007.02193.x
Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry
K. Kushitani (2008)
10.1093/JNCI/64.5.1263
Basic issues in population screening for cancer.
P. Cole (1980)



This paper is referenced by
10.1097/PAS.0000000000000616
BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas
H. Hwang (2016)
10.4103/1742-6413.170726
Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
A. Hjerpe (2015)
The role of inflammasomes in asbestos-induced mesothelial to fibroblastic transition
Joyce K. Thompson (2017)
10.1007/978-3-030-16884-1_7
Pathological Diagnosis of Mesothelioma
Gabriella Fontanini (2019)
10.1007/978-3-319-99510-6_2
Pathology of Selected Primary and Metastatic Tumors of Peritoneum
Kozlov A. Nikolay (2019)
BIBLIOGRAPHIC REVIEW July 2016 Third Consensus Conference on Malignant Pleural Mesothelioma: State-of-the-art and recommendations
(2016)
10.1055/s-0034-1365157
Zytopathologische Ergussdiagnostik in der berufsgenossenschaftlichen Begutachtung von Asbest-assoziierten malignen Mesotheliomen und Lungenkarzinomen Pleural Effusion Cytology of Asbestos-Associated Malignant Mesothelioma and Lung Carcinoma in the Diagnosis of Occupational Diseases by the Statutory
S. Biesterfeld (2014)
10.4415/ANN_15_01_09
Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines.
V. Ascoli (2015)
10.1016/J.ANNPAT.2016.01.005
Apport de l’expression protéique de BRCA1 associated protein 1 (BAP1) dans le diagnostic des mésothéliomes malins diffus pleuraux : une analyse cytologique et histologique comparative sur une série de 50 patients
A. Jaouen (2016)
10.1007/978-3-319-40618-3_37
Malignant pleural mesothelioma.
D. Ettinger (2012)
10.1038/ng.3520
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
R. Bueno (2016)
10.1097/PAS.0000000000000529
Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens
H. Hwang (2016)
10.1080/14656566.2016.1176145
Advances in treatment of mesothelioma
C. Maggioni (2016)
10.1016/J.RMCLC.2015.04.020
ASPECTOS DIAGNÓSTICOS Y TERAPÉUTICOS EN EL MESOTELIOMA PLEURAL MALIGNO
Pinto Rodríguez (2015)
10.1183/16000617.0019-2016
Malignant pleural effusion: from bench to bedside
I. Psallidas (2016)
10.1002/dc.24395
Effusion cytology of malignant mesothelioma enables earlier diagnosis and recognizes patients with better prognosis.
Sulaf Abd Own (2020)
10.1016/j.ejso.2020.02.011
Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.
S. Kusamura (2020)
10.1111/cyt.12641
Clinicopathological features of immunoglobulin G4‐related pleural lesions and diagnostic utility of pleural effusion cytology
S. Kasashima (2019)
10.1002/dc.24475
HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion.
K. Hiroshima (2020)
10.1080/10937404.2016.1195320
Pathology analysis for mesothelioma study in the United Kingdom: Current practice and historical development
Bruce W. Case (2016)
10.1016/J.LUNGCAN.2019.05.017
Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups.
Selina Tsim (2019)
10.1016/j.humpath.2015.02.006
Prognostic factors in malignant pleural mesothelioma.
B. Davidson (2015)
10.1007/s11748-020-01295-5
Clinical feature of diagnostic challenging cases for pleural biopsy in patient with malignant pleural mesothelioma
Masaki Hashimoto (2020)
10.4103/0019-5278.146897
Global mesothelioma epidemic: Trend and features
C. Bianchi (2014)
10.1093/jjco/hyz032
Cryobiopsy during flex-rigid pleuroscopy: an emerging alternative biopsy method in malignant pleural mesothelioma. A comparative study of pathology.
T. Nakai (2019)
10.6092/1828-6550/APMB.106.1.2018.SD2
Pleural diffuse mesothelial lesions: A challenge for pathologists
Antonio Ieni (2018)
10.1007/978-3-319-52619-5_36-1
Radiation Therapy in Mesothelioma
Jonas Willmann (2019)
10.1016/j.prp.2016.07.010
Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach.
V. Ascoli (2016)
10.1016/j.jprot.2018.09.018
Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma.
Reuben White (2019)
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
10.1016/j.ccm.2017.11.001
Palliative Care and Interventional Pulmonology.
Muhammad Sajawal Ali (2018)
10.1093/ejcts/ezy258
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar